Prostate cancer is one of most frequently diagnosed cancer in Western countries and is the second most common cancer in men, following lung cancer, worldwide[@b1][@b2]. In 2015, up to 220,800 men were diagnosed with prostate cancer, and 27,540 men will die of it in the United States[@b1]. The incidence and mortality rates of prostate cancer vary markedly among different ethnic groups, with the lowest rates found in China and other parts of Asia and the highest rates detected in Western populations[@b3]. The etiology of prostate cancer comprises multiple factors. Established risk factors for prostate cancer included obesity, old age, ethnicity, androgen, and environmental factor, androgen, and diet[@b4][@b5][@b6][@b7]. There are some studies addressing systematic inflammation conditions and immune response that contribute to prostate tumorigenesis[@b8][@b9].

Allergy-related carcinogenesis is a topic of interest but has generated considerable controversy. Considering the impact of the prostate cancer risk potentially resulting from allergic diaseases, a number of studies have explored the association between allergic diseases and prostate cancer risk[@b10][@b11][@b12][@b13][@b14][@b15][@b16][@b17][@b18][@b19]. However, individual studies have yielded inconsistent or conflicting findings, possibly caused by limitation associated with an individual study. In a previous meta-analysis of studies (only included nine studies), asthma, hay fever and allergy were not associated with prostate cancer risk, but not for atopy[@b20]. Two additional studies were not included in the meta-analysis[@b21][@b22]. Subsequent publishing studies have also found inconsistent results of associations between allergic disease and prostate cancer risk, with positive association[@b23][@b24][@b25][@b26], inverse association[@b27], and no association[@b28][@b29][@b30][@b31]. To shed light on these contradictory results and to more precisely evaluate the relationship among allergic diseases and prostate cancer, we performed an up-dated meta-analysis of published studies. Nevertheless, clarifying a relationship might emphasize the importance of considering additional preventative methods for prostate cancer. The study was reported in accordance with the Preferred Reporting Items for Systematic Reviews[@b32].

Results
=======

Literature search
-----------------

Following the development of our search strategy, 1,890 records were initially retrieved. After excluding the duplicates and articles that did not meet the inclusion criteria, we reviewed 34 possible relevant studies in full-text. A total of 14 studies were excluded for the following reasons: Two articles were covered the same population[@b27][@b31]; six articles were narrative reviews[@b33][@b34][@b35][@b36][@b37][@b38]; one article reported the association allergic disorders and pancreatic cancer[@b39]; and six articles were not related to outcome of interest[@b40][@b41][@b42][@b43][@b44][@b45]. Finally, 20 studies that met inclusive criteria were included in the meta-analysis ([Fig. 1](#f1){ref-type="fig"}).

Study characteristics
---------------------

The [Tables 1](#t1){ref-type="table"} and [2](#t2){ref-type="table"} shows the descriptive data for all included studies. A total of 20 studies, comprising 5 case-control studies with 2,924 incident cases and 7,175 controls and 15 cohort studies including 16,526 cases and 1,681,562 pariticipants, contributed to the meta-analysis. These studies were published from 1985 to 2015. The number of prostate cancer patients ranged from 1 to 6,294 in the case-control studies and from 10 to 1,936 in the cohort studies. Ten studies were conducted in Europe[@b10][@b12][@b13][@b14][@b17][@b23][@b24][@b28][@b29][@b30], six in the North America[@b11][@b16][@b18][@b19][@b22][@b31], two in Australia[@b15][@b25] and two in Asia[@b21][@b26]. Eighteen studies reported findings for prostate cancer incidence[@b10][@b11][@b12][@b13][@b14][@b16][@b17][@b18][@b19][@b21][@b22][@b23][@b24][@b25][@b26][@b28][@b29][@b31], whereas only two studies reported results for prostate cancer mortality[@b16][@b30]. We included a total of 5,757 prostate cancer deaths, 16,526 prostate cancer cases in the meta-analysis. The maximum numbers (1,102,247) of participants were from the Canada prospective study and minimum number (1,522) were from Australia prospective study in the cohort studies, while the maximum incident patients (1,936) were from the Canada Montreal PROtEuS study and minimum incident patients (10) were from Japan study in the case-control studies. The exposure categories that were measured were: 1) asthma; 2) hay fever (rhinitis); 3) atopy; and 4) any allergy (atopy and/or asthma, hay fever, or other allergic disease). For the assessment of allergic conditions, allergen-specific IgE measurement, skin prick testing, self-reported questionnaire, interviews by medical staff, and hospital discharge register were employed. For the assessment of prostate cancer, fourteen studies reported that cancers were histologically confirmed or were identified from national/regional cancer registeries, which we assumed verified the cancer pathologically. The remaining studies based their cancer diagnoses on different criteria; admission/discharge diagnoses; an automated general practice database; a linked national death register; review of hospital and nursing home recorder and death certificates. Six studies were designed to evaluate OR[@b10][@b17][@b18][@b19][@b22][@b31], five evaluated HR[@b15][@b25][@b26][@b29][@b30], three evaluated RR[@b11][@b16][@b21][@b28], while five studies compared observed cancer incidence rates in cohort of patients with asthma or hay fever/allergic rhinitis against expected numbers estimated from population-based cancer registries and their effect estimates were standardized incidence ratio (SIR)[@b13][@b14][@b23][@b24] or standardized mortality ratio(SMR)[@b12].

Adjusted effect estimates could be determined for most cohort and case-control studies. Most risk estimates were adjusted for age (n = 12)[@b10][@b11][@b15][@b17][@b18][@b19][@b22][@b25][@b26][@b28][@b30][@b31], smoking (n = 10)[@b10][@b11][@b15][@b16][@b17][@b18][@b19][@b25][@b28][@b29] and body mass index (n = 8)[@b10][@b15][@b16][@b17][@b25][@b28][@b29][@b30]. Some studies were also controlled for alcohol consumption (n = 5)[@b10][@b16][@b17][@b25][@b29] and race (n = 3)[@b16][@b19][@b28], but few studies were adjusted for family history of prostate cancer (n = 2), total energy intake (n = 1)[@b25], and intake of vegetable and red meat (n = 1)[@b16]. None of the studies were adjusted for exposure to heavy metals and androgen.

The methodological quality of the included studies was generally good. The NOS scores ranged from five to seven ([Table 3](#t3){ref-type="table"}). The median NOS score was 6.0.

Asthma and risk of prostate cancer
----------------------------------

The association of asthma with prostate cancer was investigated in 17 studies[@b10][@b11][@b12][@b13][@b14][@b15][@b16][@b17][@b18][@b21][@b22][@b24][@b25][@b26][@b28][@b30][@b31]. Thirteen studies reported HR/RR/OR[@b10][@b11][@b15][@b16][@b17][@b18][@b21][@b22][@b25][@b26][@b28][@b30][@b31], while four studies reported the SIR/SMR[@b12][@b13][@b14][@b24]. The combined relative risk was 1.04 (95%CI: 0.92--1.17), with significant heterogeneity (P~for\ heterogeneity~ = 0.000; *I*^2^ = 73.2%), while the pooled SIR was 1.00 (95%CI: 0.68--1.47), with significant heterogeneity (P~for\ heterogeneity~ = 0.000; *I*^2^ = 97.7%) ([Fig. 2](#f2){ref-type="fig"}). In subgroup and sensitivity analysis, the results showed basically consistent with the overall analysis ([Table 4](#t4){ref-type="table"}). When we stratified the analysis by geographic region, the pooled RR was 0.95 (95%CI: 0.81--1.12) for studies conducted in North America, 0.90 (0.81--1.00) for studies conducted in Europe, and 4.55 (0.23--89.94) for studies conducted in Asia. In the subgroup analysis stratified by NOS quality, the combined RR was 1.90 (95%CI: 0.29--12.61) for low quality studies and 1.02 (95%CI: 0.93--1.13) for high quality studies. We restricted each analysis to study design, the combined RR was 1.02 (95%CI: 0.91--1.15) among case-control studies and 1.20 (94%CI: 0.69--2.09) among cohort studies, respectively. Nevertheless, when we stratified the analysis by adjusted for age, race, BMI, cigarette smoking and alcohol drinking, asthma was also not associated with risk of prostate cancer. In a sensitivity analysis, similar results were observed, which ranged from 1.01 (95%CI: 0.88--1.16) with significant heterogeneity (P~for\ heterogeneity~ = 0.000, *I*^2^ = 73.7%) (excluding the study by Severi G *et al.*[@b25]) to 1.07 (95%CI: 0.93--1.23) with significant heterogeneity (P~for\ heterogeneity~ = 0.000, *I*^2^ = 69.2%) (excluding the study by Platz *et al.*[@b28]). Only four of studies on asthma specially investigated advanced prostate cancer risk (advanced prostate cancer was defined as T3-4 and PSA \> 50 ng/ml or Gleason grade ≥ 8) and asthma[@b25][@b28], the summary RR was 0.86 (95%CI: 0.54--1.37), with significant heterogeneity (P~for\ heterogeneity~ = 0.079; *I*^2^ = 67.6%). Egger funnel plot asymmetry test (P = 0.865) and Begg rank correlation test (P = 0.502) were performed to assess publication bias and the funnel plot symmetry ([Fig. 3](#f3){ref-type="fig"}) was examined. Finally, no proof of publication bias was obtained. Because of limited number of studies, we fail to conduct subgroup and sensitivity, publication analysis for studies reported the SIR or SMR.

Hay fever and risk of prostate cancer
-------------------------------------

The association of hay fever with prostate cancer was examined in 7 studies[@b10][@b11][@b16][@b18][@b23][@b28][@b31]. The six studies reported RR/OR[@b10][@b11][@b16][@b18][@b28][@b31] ([Fig. 4](#f4){ref-type="fig"}), while SIR was reported in only one study, which reported a positive association between hay fever/allergic rhinitis and prostate cancer risk[@b23]. The combined relative risk was 1.04 (95%CI: 0.99--1.09), with low heterogeneity (P~for\ heterogeneity~ = 0.428; *I*^2^ = 0.0%). Subgroup and sensitivity analysis produced similar results ([Table 4](#t4){ref-type="table"}). In subgroup analysis stratified by geographic region, asthma was not associated with risk of prostate cancer (RR: 0.97; 95% CI: 0.88--1.06) in the four studies in North Ameria, but not in the two studies in Europe (RR:1.07; 95%CI: 1.01--1.13). Compared with a low NOS score (RR = 1.02, 95%CI: 0.94--1.11), the association was higher among studies with high NOS score (RR = 1.15, 95% CI: 0.78--1.70). When we restricted each analysis to study design, the combined RR was 1.03 (95%CI: 0.93--1.14) among case-control studies and 1.02 (95%CI: 0.76--1.36) cohort studies, respectively. When the analysis was restricted to studies adjusted for race, BMI and cigarette smoking, we found no association between asthma and prostate cancer, but not for studies adjusted for age and alcohol drinking. In a sensitivity analysis, similar results were observed, which ranged from 0.97 (95%CI: 0.88--1.06) with low heterogeneity (P~for\ heterogeneit~ = 0.360, *I*^2^ = 9.0%) (excluding the study by Platz *et al.*[@b28]) to 1.07 (95%CI: 1.01--1.13) with significant heterogeneity (P~for\ heterogeneit~ = 0.025, *I*^2^ = 58.4%) (excluding the study by Turne *et al.* which reported the association between asthma and mortality of prostate cancer[@b16]). Both the Begg rank correlation test (P = 0.707) and the Egger linear regression test (P = 0.775) in the meta-analysis indicated no significant publication bias. Because number of included studies less than 10, we did not perform the funnel plot.

Atopy and risk of prostate cancer
---------------------------------

The association of atopy with prostate cancer was investigated in 3 studies[@b10][@b15][@b29]. The combined relative risk was 1.25 (95%CI: 0.74--2.10), with notable heterogeneity (P~for\ heterogeneity~ = 0.024; *I*^2^ = 73.2%) ([Fig. 5](#f5){ref-type="fig"}). In subgroup and sensitivity analysis, the results showed basically consistent with the overall analysis ([Table 4](#t4){ref-type="table"}). The include studies achieved six or more stars and considered to be of high quality, so the result was consistent with overall analysis. When the analysis was restricted to studies adjusted for age, race, BMI, alcohol drinking and cigarette smoking, we found no association between asthma and prostate cancer. In a sensitivity analysis, similar results were observed, which ranged from 1.05 (95%CI: 0.62--1.77) with low heterogeneity (P~for\ heterogeneity~ = 0.036, *I*^2^ = 77.6%) (excluding the study by Talbot-Smith *et al.*[@b15]) to 1.59 (95%CI: 0.93--2.71) with significant heterogeneity (P~for\ heterogeneity~  = 0.193, *I*^2^ = 41.0%) (excluding the study by Skaaby *et al.*[@b29]). Both Egger's test (P = 1.000) and Bgger's test (P = 0.761) showed no publication bias. Because number of included studies less than 10, we did not perform the funnel plot.

Any allergy and risk of prostate cancer
---------------------------------------

The association of asthma with prostate cancer was investigated in 6 studies[@b10][@b11][@b16][@b19][@b22][@b31]. The combined relative risk was 0.96 (0.86--1.06), with low heterogeneity (P~for\ heterogeneity~ = 0.287; *I*^2^ = 19.3%). Subgroup and sensitivity analysis yielded similar result ([Fig. 6](#f6){ref-type="fig"}). In subgroup and sensitivity analysis, the results showed basically consistent with the overall analysis ([Table 4](#t4){ref-type="table"}). When we stratified the analysis by geographic region, the pooled RR was 0.96 (95%CI: 0.84--1.10) for 5 studies conducted in North America, 0.98 (95%CI: 0.66--1.45) for 1 studies conducted in Europe. Stratifying by study design, the combined RR was 1.06 (95%CI: 0.84--1.33) among case-control studies and 0.88 (95%CI: 0.75--1.04) among cohort studies, respectively. Compared with a low NOS score (SMR = 2.08, 95%CI: 0.73--5.91), the association was significant among studies with high NOS score (OR = 1.51, 95%CI: 1.14--1.98). In subgroup analysis adjusted for risk factors, including age, race, smoking and alcohol drinking, the results was consistent with overall analysis. In a sensitivity analysis, similar results were observed, which ranged from 0.93 (95%CI: 0.86--1.00) with low heterogeneity (P~for\ heterogeneity~ = 0.612, *I*^2^ = 0.0%) (excluding the study by Mill *et al.*[@b11]) to 0.99 (95%CI: 0.82--1.19) with significant heterogeneity (P~for\ heterogeneity~ = 0.194, *I*^2^ = 34.1%) (excluding the study by Turner *et al.*[@b16]). The Begg rank correlation test (P = 0.133) and Egger linear regression test (P = 0.489) also indicated no evidence of publication bias. Because number of included studies less than 10, we did not perform the funnel plot.

Discussion
==========

Allergic diseases (immune mediated conditions), encompassing hay fever, allergic asthma and atopy, are caused by inappropriate immunological response to antigens that do not elicit response in most individuals. Allergy-related carcinogenesis is a topic of interest but has generated considerable controversy. There has been a long-standing interest in determining whether individuals with allergic diseases have an altered risk of developing cancer. Several studies investigated the association between allergic diseases and specific cancers. Asthma, hay fever, and atopy have been associated with the risk of several specific cancers, such as pancreatic cancer, lymphomas, brain tumors, breast cancer and leukemia, although inconsistently[@b10][@b14][@b15][@b46][@b47]. Allergic diseases could theoretically both prevent and induce the development of several specific cancers. Two hypotheses that attempt to explain the possible mechanism between allergic diseases and cancer are immune surveillance and the antigenic stimulation theory[@b48]. Allergy might enhance the human immune system to recognize and eliminate cancer cells. In contrast, the antigenic stimulation hypothesis proposes that hyperactive immune conditions trigger chronic cellular inflammation, resulting in DNA mutation in dividing cells and inevitably leading to cancer development[@b49]. The determination of whether asthma, hay fever, atopy and any allergy are associated with prostate cancer has been evaluated in a small number of studies. The small number of prior studies evaluating allergic disease and prostate cancer has not produced consistent results, inverse[@b12][@b16][@b18], null[@b13][@b14][@b15][@b17][@b28][@b29][@b30][@b31], and positive associations[@b10][@b11][@b19][@b21][@b22][@b23][@b24][@b25][@b26][@b27] have been reported. The inconsistent results of previous studies may be due to insufficient study sample size, publication bias, selection bias, lack of adjustment for confounding factors, and the use of different definitions of allergic diseases. A recent meta-analysis of the few studies suggested that asthma (N = 8, pooled RR: 0.93; 95%CI: 0.76--1.15), hay fever (N = 5, pooled RR: 0.96; 95%CI: 0.87--1.05), and any allergy (N = 4, pooled RR: 1.01; 95%CI: 0.87--1.17), but not for atopy (N = 3, pooled RR: 1.43; 95%CI: 1.08--1.91)[@b20]. However, studies published subsequent to this report have reported inconsistent results[@b23][@b24][@b25][@b26][@b27][@b28][@b29][@b30][@b31]. In addition, the relation between allergic diseases and cancer risk remain unclear, and appear to be site-specific, we conducted an up-dated meta-analysis to summarize the current proof to evaluate the association between allergic conditions and prostate cancer risk. The meta-analysis suggested that there is little observational support for the two theories in the development of prostate cancer. The effect of hyperreactive state and/or immune surveillance theories maybe mutually offset in the body.

The present meta-analysis exhibited several strengths, compared to the previous published meta-analysis. The first research highlight of this meta-analysis is its large sample size. The large number of total cases provided high statistical power to quantitatively evaluate the association between allergic conditions and prostate cancer risk. In addition, we expand the meta-analysis and the association between different geographic regions and study design, adjusted for covariates was also explored. Second, publication bias is a potential concern in any meta-analysis because small studies with null results do not get published. However, in our meta-analysis, we found little evidence of publication bias.

Nevertheless, there are some several limitations in the present meta-analysis. First, case-control studies have intrinsic limitations, such as selective bias and recall or memory bias. This limitation can partly explained the different results between case-control and cohort studies in the stratified analysis. Second, we cannot exclude the possibility that the observed null relationship between allergic disorders and prostate cancer risk is attributed to confounding factors. Majority of the studies were adjusted for potential confounding factors, but not all potential confounders were adjusted in every study. Although the allergic conditions and prostate cancer share common some potential confounders, such as cigarette smoking, alcohol drinking, old age, BMI and race, in analysis stratified by adjusting the smoking status, age, alcohol drinking BMI and race, similar results were obtained. Third, measurement error in assessment of allergic conditions are known to bias effect estimates, however, none of included studies in the meta-analysis made any corrections for measurement errors. An accurate assessment of allergic conditions remains a challenge, because these measures are based on different assessment methods, such as allergen-specific IgE measurement, skin prick testing, self-reported questionnaire, interviewed by medical staff, and hospital discharge register. Diagnosis of allergic conditions was largely based on a self-reported. Only a few studied were based on measurements that may be condisered to be more objective: serum LgE or skin prick tests. The increasing errors in measurements become inevitable. The imprecise measurement of allergic disorders might have attenuated the true associations. Fourth, potential sources of between-study heterogeneity, which is common in meta-analysis, should be explored although the low heterogeneity was found between hay fever or atopy and prostate cancer risk. Results from subgroup and sensitivity analysis indicated that geographic region, study design, quality of NOS may be potential sources of heterogeneity. Thirds, in subgroup analysis, there was a marginally positive association between hay fever and prostate cancer risk in studies that adjusted for age and alcohol drinking and conducted in the Europe, but a null association among studies adjusted for cigarette smoking and race. Due to the numerous comparisons and few included studies, this positive finding may have been a chance finding. It indicated that more relevant articles are needed to further explore this association. Fifth, analysis of the length of the induction period allows for characterising an exposure--outcome relationship and for falsifying the pathway assumed. The longer the supposed time sequence between the exposure and the occurrence of the outcome, the more crucial to analyze the empirical induction period. The average follow-up ranged from 5.05 years to 43 years among included cohort studies. Patients were followed up over five years in majority of the studies (92.8%). Therefore, the observation period in the included cohort studies covered a reasonable induction period. Overall, these limitations may affect our final conclusions.

In the meta-analysis, we found no indication of an association between allergic conditions (asthma, atopy, hay fever, or any allergy) and risk of prostate cancer, and there is little observational support for the immune surveillace theory or antigenic stimulation theory in the development of prostate cancer risk. However, these results should be carefully interpreted because of the significant heterogeneity among studies and potential confounders. Additional large-scale and high-quality prospective studies are needed to confirm the association between allergic conditions and risk of prostate cancer.

Methods
=======

Literature search
-----------------

A literature search was performed in March 15, 2016 without restriction to regions, publication types, or languages. The primary sources were the electronic databases of Pubmed and Embase databases. To identify eligible studies, the main search employed various combinations of Medical Subject Headings (MeSH) and non-MeSH terms "prostate carcinoma" OR "prostatic cancer" OR "prostate cancer" OR "prostatic carcinoma" combined with "asthma" OR "asthma\*" OR "allergy" OR "allerg\*" OR "atopy". The main search was completed independently by two investigators. Any discrepancy was solved by consultation of an investigator, not involved in the initial procedure. Moreover, the reference lists of all the studies and published systematic reviews, meta-analysis were also screened to identify other potentially eligible studies.

Study selection
---------------

To minimize the differences between studies, we imposed the following methodological restrictions for the inclusion criteria: 1) study design of interest was either cohort or case control study 2) the exposure of interest was allergic conditions (asthma, atopy, hay fever and "any allergy"); 3) the outcome was prostate cancer; 4) the study reported enough information to extract effect estimates and the corresponding 95% confidence intervals. In case of multiple publications, only the most recent or comprehensive one was considered eligible. Two authors (JKS and XHY) independently evaluated the eligibility of all retrieved studies and disagreements were resolved through discussion or consultation with a third author (LHG).

Data extraction
---------------

Data from the included studies were extracted and summarized independently by two of the authors using a pre-standardized data extraction form. Any disagreement was resolved by the senior author (ZWD). The following data were extracted from each study: first author, publication year, study design, country, sex, total number of cases and subjects for cohort studies, total number of cases and controls for case-control studies, assessment methods for allergic diseases, quantitative effect estimates (expressed as an odds ratio, hazard risk, relative risk, standardized mortality ratio, or standardized incidence ration) and 95%CI and variables adjusted for in the meta-analysis. The OR in one study[@b18] was not extracted, thus, we computed the crude risk estimates and corresponding CI. Two review authors (SJK and ZJG) independently extracted data from the selected studies. Any disagreements were resolved through discussion and consensus.

Quality assessment
------------------

Two review authors (SJK and ZJG) independently assessed the risk of bias using the Newcastle-Ottawa Scale (NOS), which consists of three factors: patient selection, comparability of the study groups, and assessment of outcome. A score of 0--9 (allocated as stars) was allocated to each study[@b50][@b51]. The studies achieving six or more stars were considered to be of high quality.

Statistical analysis
--------------------

Because the incidence of prostate cancer risk was low, the OR/HR was considered as approximation of RR, SMR was also considered as equivalent of SIR[@b52]. We computed the combined RR and SIR and corresponding 95%CI from the estimated reported in each study. The aggregated results and 95%CIs for effect sizes were calculated using inverse-variance weighted random-effects meta-analysis, which incorporated both within-study and between-study variability[@b53]. *I*^2^ was used to assess heterogeneity across studies, with *I*^2^ values of 0%, 25%, 50% and 75% representing no, low, moderate and high heterogeneity, respectively. Subgroup analysis was stratified by geographic region, study design, quality of NOS scale, body mass index (BMI) and whether the study adjusted for risk factors, including age, race, alcohol drinking and smoking. The sensitivity analysis was also conducted by removing one study at a time and the rest analyzed to determine whether an individual study affected the aggregate result or not. Small study bias, consistent with publication bias, was evaluated by statistical tests (Begg rank correlation test[@b54] and Egger's linear regression test[@b55]), the visual examination of funnel plot when the number of included studies ≥10, and the results were considered to indicate publication bias when P \< 0.10. All statistical analyses were conducted using Stata version 13.1 (Stata Corp., College Station, TX, USA).
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###### Characteristic of cohort/nested case-control studies included in the meta-analysis.

  Study             Year      Country                                          Study design                                                No. of cases              Cohort size   Study period           Age, Median (Range), yrs                       Exposure                                                Exposure assessment                                                                                                      Cancer identification                                                                   Follow-up period (years)                                                                                                                                                                       Adjustment for covariates
  ---------------- ------ ---------------- ------------------------------------------------------------------------------------ ----------------------------------- ------------- -------------- ------------------------------------------- -------------------------------- ------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Mcwhorter         1988        USA                                A prospective cohort study (NHANESI)                                         34                      6108        1971--1984                   NA(25--74)                            Any allergy                                         The physician-diagnosed allergy                                                                              Hospital or nursing home records or on death certificate                                                             10                                                                                                                                                                         Adjusted for age, race, and smoking status.
  Mills             1992        USA                                           A cohort study                                                    180                    34,198       1977--1982                       NA                       Asthma; hay fever; any allergy                    A detailed life-style questionnaire on medical history                                                                            Medical records and cancer registries                                                                      6                                                                                                                                                             Adjusted age, smoking history, and time since last physician contact.
  Kallen            1993       Sweden                                         A cohort study                                                    671                    64,346       1969--1983                       NA                                   Asthma                                             Hospital discharge register                                                                                     Swedish cancer registries and death registries                                                                  14                                                                                                                                                                                              NA
  Vesterinen        1993      Finland                                         A cohort study                                                    256                    77,952       1970--1987                   NA(35--84)                               Asthma                            Finish social insurance institution's file of asthma patients                                                                                Finnish cancer registry                                                                             17                                                                                                                                                                                              NA
  Eriksson          1995       Sweden                                         A cohort study                                                     1                      6,593       1976--1989                   31(16--80)                               Asthma                                                  Skin prick tests;                                                                                                 Swedish national tumor registries                                                                        13                                                                                                                                                                                              NA
  Talbot-Smith      2002     Australia                                  A prospective cohort study                                              86                      1,522       1981--1999               Men:50.7;Women:50.0                 Asthma; hay fever; atopy                  Self-reported physician-diagnosed allergy and skin prick testing                                                           Linkage to death registrations and Australian cancer registry                                                          8                                                                                                                                                                     Adjusted for age, smoking status, and body mass index.
  Gonzalez-Perez    2005       Spain                                   A nested case-control study                                              407                     9,488       1994--2000                   NA(20--79)                               Asthma                                        Automated general practitioner records                                                                                   Automated general practitioner records                                                                      6                                                             Adjusted for age, calendar year, BMI, alcohol intake, smoking status, prior comorbidities (cardiovascular disease, diabetes, osteoarthirtis, and rheumatoid arthritis), health services utilization, use of aspirin, NSAID, and paracetamol using logistic regression.
  Turner            2005       Canada                                   A prospective cohort study                                       5,674 (mortality)            1,102,247     1982--2000                     NA(≥30)                    Asthma; hay fever; any allergy                          Self-reported physician-diagnosed allergy                                                                                           National death index                                                                               18                                                                                                           Adjusted for race, smoking, education, body mass index, exercise, alcohol drinking, family history of prostate cancer, and consumption of vegetables, fat, and red meat.
  Ji                2009       Sweden                                         A cohort study                                                   1008                    140,425      1965--2004                       NA                                   Asthma                                       The Swedish hospital discharge register                                                                                      Cancer register-identified cases                                                                         40                                                                                                                                                                                              NA
  Severi            2010     Australia           A prospective cohort study (Melbourne Collaborative Cohort Study (MCCS))                      1,179                   16,394       1990--2007                   NA(27--81)                               Asthma                           A structure interview schedule and history of medical conditions                                                                          Australia state cancer registry                                                                        13.4                                                                                                                       Adjusted for age, country of birth, education, body mass index, fat and fat-free mass, smoking, alcohol consumption, and total energy intake.
  Hemminki          2014       Swede                                          A cohort study                                                    404                    138,723      1964--2010                       NA                        Hay fever/allergic rhinitis                                   Hospital Discharge Register                                                                                                 Swedish Cancer Registry                                                                             NA                                                                                                                                                                                              NA
  Skaaby            2014       Danish                          A prospective population-based cohort study                                      175                    14,849       1976--2008    Nonatopic:46.3 ± 10.9; Atopic 43.7 ± 10.4               Atopy                                       Serum specific IgE positivity measurements                                                                                         Danish cancer registry                                                                             11.8                                                                                                                                   Adjusted for age (age is underlying time axis), education, physical activity, smoking habits, alcohol intake, and BMI.
  Platz             2015       Sweden       A prospective population-based cohort study (Health Professionals Follow-up Study)                 6294                    47, 880      1986--2012                   NA(40--75)                          Asthma; hayfever                                               Queationnaire                                                                                                  Medical and pathology reports (90%)                                                                       26              Adjusted for age, race (African-American, Asian, other ancestry and white), first-degree family history of prostate cancer, height (inches), body mass index (BMI, kg/m2, updated), BMI at the age of 21 years (kg/m2), vigorous physical activity (MET-hours/week, updated), diabetes (updated) and cigarette smoking in the past 10 years (pack-years, updated).
  Su                2015   Taiwan (China)                          A population-based case-cohort study                                         74                     12,372       1997--2008                54.87(15--65^+^)                            Asthma                                                 Medical claims data                                      Prostate cancer claim records and histopathologic findings or significantly elevated prostate-specific antigen with radiologic evidence of metastasis             5.05                                                                                              Adjusted for age, residential area, insurance premium, hypertriglyceridemia, hypertension, diabetes mellitus, chronic obstructive pulmonary disease, duration of hospitalization, and mortality.
  Taqhizadeh        2015    Netherlands                          A general population-based cohort study                         83(mortality and hospitalization)      8,465       1965--2008                   NA(20--65)                               Asthma               Peripheral blood eosinophil counts; Skin prick tests; Serum total Immunoglobulin E (IgE)                                                                Hospital admission register                                                                           43                                                                                                                             Adjusted for age, Forced Expiratory Volume in 1 s (FEV 1) as % of predicted, BMI (all at the first survey), and place of residence.

###### Characteristic of case-control studies included in the meta-analysis.

  Study      Year        Country                                 Study design                            No. of cases   No. of controls   Study period   Age, Median (Range), yrs                 Exposures                                               Exposure assessment                                       Cancer identification                                                           Adjustment for covariates
  --------- ------ ------------------- ---------------------------------------------------------------- -------------- ----------------- -------------- -------------------------- --------------------------------------- --------------------------------------------------------------------------------- ----------------------------------- --------------------------------------------------------------------------------------------------------------------------------
  Vena       1985          USA                        A retrospective case-control study                     263             1562          1957--1965               NA                        Asthma, hay fever                       Self-completed questionnaire and medical history interview                   Admissions with cancer                                                         Adjusted for age and smoking.
  Ohrui      2002         Japan                              A case-control study                             10             1202          1995--2000      Case:68; control:69                     Asthma                                                 Clinical diagnosis                                         Clinical diagnosis                                                                         NA
  Wang       2006        Germany                             A case-control study                            318             1904          2000--2003           NA(50--74)          Asthma, hay fever, atopy, any allergy   Allergen-specific LgE measurement; questionnaire on physician diagnosed allergy   Histologically confirmed cancers    Adjusted for age, education, body mass index, family history of cancer (first degree), smoking status and alcohol consumption.
  El-Zein    2010   Canada (Montreal)               A population-based case-control study                    397              512          1979--1986           NA(35--70)                     Ashtma, eczema                                 Self-reported history of medical conditions                     Histologically confirmed cancers.                            Adjusted for age, income, respondent status, ancestry, smoking, and farming.
  Weiss      2014   Canada (Montreal)   A population-based case-control study (Montreal PROtEuS study)       1936            1995          2005--2009    Case:63.6; Control 64.8         Asthma, allergy; hay fever                                Self-reported asthma and allergy                            Que´becn Tumour registery (80%)                                 Adjusted for age, ancestry and familial history of prostate cancer.

###### Quality assessment of eligible studies based on Newcastle-Ottawa scale.

  Author            year   Selection   Comparability   Exposure
  ---------------- ------ ----------- --------------- ----------
  Vena              1985       2             1            2
  Mcwhorter         1988       3             1            2
  Mills             1992       3             1            1
  Kallen            1993       3             0            2
  Vesterinen        1993       3             0            2
  Eriksson          1995       3             0            2
  Ohrui             2002       3             0            2
  Talbot-Smith      2002       3             1            2
  Lightfoot         2004       3             1            2
  Turner            2005       3             2            2
  Gonzalez-Perez    2005       3             2            2
  Wang              2006       3             2            2
  Ji                2009       3             0            2
  Severi            2010       3             2            2
  Hemminki          2014       3             0            2
  Weiss             2014       3             1            2
  Skaaby            2014       3             2            2
  Platz             2015       3             2            2
  Su                2015       3             2            2
  Taqhizadeh        2015       3             2            2

###### Results of subgroup analysis of asthma, hay fever, atopy, and any allergy.

  Subgroup analysis                                         Asthma       Hay fever       Atopy   Any allergy                                                                                                            
  -------------------------------------------------------- -------- ------------------- ------- ------------- --- ------------------ ------ ------- --- ------------------ ------ ------- --- ------------------ ------ -------
  Total                                                       13     1.04(0.92--1.17)    73.2       0.000      6   1.04(0.99--1.09)   0.0    0.428   3   1.25(0.74--2.10)   73.2   0.024   6   0.96(0.86--1.06)   19.3   0.287
  Study design                                                                                                                                                                                                          
   Cohort study                                               8      1.02(0.91--1.15)    68.0       0.003      3   1.03(0.93--1.14)   56.1   0.103   2   1.31(0.43--4.01)   81.9   0.019   3   1.06(0.84--1.33)   48.9   0.142
   Case-control study                                         5      1.20(0.69--2.09)    82.5       0.000      3   1.02(0.76--1.36)   0.0    0.848   1   1.35(1.00--1.83)    NA     NA     3   0.88(0.75--1.04)   0.0    0.497
  Geographic region                                                                                                                                                                                                     
   North America                                              5      0.95(0.81--1.12)    20.9       0.281      4   0.97(0.88--1.06)   0.0    0.699                                         5   0.96(0.84--1.10)   35.2   0.187
   Europe                                                     4      0.90(0.81--1.00)     0.0       0.698      2   1.07(1.01--1.09)   0.0    0.522   2   1.05(0.62--1.77)   77.2   0.036   1   0.98(0.66--1.45)    NA     NA
   Asia                                                       2      4.55(0.23--89.94)   94.3       0.000                                                                                                                   
   Australia                                                  2      1.36(0.98--1.90)    32.9       0.222                                            1   2.49(1.04--5.93)    NA     NA                                      
  NOS score                                                                                                                                                                                                             
   High                                                       10     1.02(0.93--1.13)    61.4       0.006      4   1.02(0.94--1.11)   33.2   0.213   3   1.25(0.79--2.10)   73.2   0.024   5   0.93(0.86--1.00)   0.0    0.612
   Low                                                        3      1.90(0.29--12.61)   90.6       0.000      2   1.15(0.78--1.70)   0.0    0.715                                         1   1.25(0.93--1.69)    NA     NA
  Adjusted for confounders or important risk factors Age                                                                                                                                                                
   yes                                                        10     1.02(0.88--1.18)    55.6       0.016      5   1.07(1.01--1.13)   0.0    0.951   2   1.59(0.93--2.71)   41.0   0.193   5   0.99(0.82--1.19)   34.1   0.194
   no                                                         3      1.04(0.92--1.17)    73.2       0.000      1   0.95(0.86--1.05)    NA     NA     1   0.79(0.53--1.18)    NA     NA     1   0.94(0.86--1.02)    NA     NA
  Race                                                                                                                                                                                                                  
   yes                                                        2      0.90(0.81--1.00)     0.0       0.769      4   1.07(0.84--1.36)   0.0    0.872                                         2   0.94(0.87--1.03)   0.0    0.380
   no                                                         11     1.10(0.93--1.29)    69.5       0.000      2   1.02(0.90--1.14)   75.9   0.042   3   1.25(0.74--2.10)   73.2   0.024   4   0.97(0.79--1.18)   44.4   0.145
  Cigarette smoking                                                                                                                                                                                                     
   yes                                                        8      0.99(0.84--1.17)    62.7       0.009      5   1.03(0.96--1.00)   17.5   0.303   3   1.25(0.74--2.10)   73.2   0.024   3   1.06(0.84--1.33)   48.9   0.142
   no                                                         5      1.17(0.88--1.56)    79.2       0.001      1   1.09(0.74--1.61)    NA     NA                                           3   0.88(0.75--1.04)   0.0    0.497
  Alcohol drinking                                                                                                                                                                                                      
   yes                                                        9      1.07(0.89--1.28)    77.2       0.000      4   1.07(1.01--1.13)   0.0    0.963   2   1.05(0.62--1.77)   77.2   0.036   5   0.99(0.82--1.19)   34.1   0.194
   no                                                         4      1.04(0.83--1.24)    65.8       0.032      2   0.95(0.85--1.05)   0.0    0.843   1   2.49(1.04--5.93)    NA     NA     1   0.96(0.86--1.06)    NA     NA
  BMI                                                                                                                                                                                                                   
   yes                                                        7      1.02(0.87--1.20)    62.8       0.013      3   1.01(0.92--1.12)   0.0    0.916   3   1.25(0.79--2.10)   73.2   0.024   2   0.94(0.87--1.02)   0.0    0.839
   no                                                         6      1.08(0.80--1.45)    78.2       0.000      3   1.12(0.85--1.48)   54.9   0.109                                         4   1.00(0.79--1.26)   50.5   0.108

[^1]: These authors contributed equally to this work.
